A A Firsov

Summary

Affiliation: Russian Academy of Medical Sciences
Country: Russia

Publications

  1. pmc Bacterial resistance studies using in vitro dynamic models: the predictive power of the mutant prevention and minimum inhibitory antibiotic concentrations
    Alexander A Firsov
    Department of Pharmacokinetics and Pharmacodynamics, Gause Institute of New Antibiotics, Russian Academy of Medical Sciences, Moscow, Russia
    Antimicrob Agents Chemother 57:4956-62. 2013
  2. doi request reprint Telavancin and vancomycin pharmacodynamics with Staphylococcus aureus in an in vitro dynamic model
    Irene Yu Lubenko
    Department of Pharmacokinetics and Pharmacodynamics, Gause Institute of New Antibiotics, Russian Academy of Medical Sciences, 11 Bolshaya Pirogovskaya Street, Moscow 119021, Russia
    J Antimicrob Chemother 62:1065-9. 2008
  3. doi request reprint Linezolid pharmacodynamics with Staphylococcus aureus in an in vitro dynamic model
    Elena N Strukova
    Department of Pharmacokinetics and Pharmacodynamics, Gause Institute of New Antibiotics, Russian Academy of Medical Sciences, Moscow, Russia
    Int J Antimicrob Agents 33:251-4. 2009
  4. pmc Comparative pharmacodynamics and antimutant potentials of doripenem and imipenem with ciprofloxacin-resistant Pseudomonas aeruginosa in an in vitro model
    Alexander A Firsov
    Department of Pharmacokinetics and Pharmacodynamics, Gause Institute of New Antibiotics, Russian Academy of Medical Sciences, Moscow, Russia
    Antimicrob Agents Chemother 56:1223-8. 2012
  5. ncbi request reprint ABT492 and levofloxacin: comparison of their pharmacodynamics and their abilities to prevent the selection of resistant Staphylococcus aureus in an in vitro dynamic model
    Alexander A Firsov
    Department of Pharmacokinetics and Pharmacodynamics, Gause Institute of New Antibiotics, Russian Academy of Medical Sciences, 11 Bolshaya Pirogovskaya Street, Moscow, 119021
    J Antimicrob Chemother 54:178-86. 2004
  6. ncbi request reprint AUC/MIC relationships to different endpoints of the antimicrobial effect: multiple-dose in vitro simulations with moxifloxacin and levofloxacin
    Alexander A Firsov
    Department of Pharmacokinetics and Pharmacodynamics, Gause Institute of New Antibiotics, Russian Academy of Medical Sciences, 11 Bolshaya Pirogovskaya Street, Moscow, 119992 Russia
    J Antimicrob Chemother 50:533-9. 2002
  7. pmc Enrichment of fluoroquinolone-resistant Staphylococcus aureus: oscillating ciprofloxacin concentrations simulated at the upper and lower portions of the mutant selection window
    Alexander A Firsov
    Department of Pharmacokinetics and Pharmacodynamics, Gause Institute of New Antibiotics, Russian Academy of Medical Sciences, 11 Bolshaya Pirogovskaya St, Moscow 119021, Russia
    Antimicrob Agents Chemother 52:1924-8. 2008
  8. ncbi request reprint Simulated in vitro quinolone pharmacodynamics at clinically achievable AUC/MIC ratios: advantage of I E over other integral parameters
    A A Firsov
    Department of Pharmacokinetics and Pharmacodynamics, Gause Institute of New Antibiotics, Russian Academy of Medical Sciences, Moscow, Russia
    Chemotherapy 48:275-9. 2002
  9. pmc In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus
    Alexander A Firsov
    Department of Pharmacokinetics, Gause Institute of New Antibiotics, Russian Academy of Medical Sciences, Moscow, Russia
    Antimicrob Agents Chemother 47:1604-13. 2003
  10. ncbi request reprint Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to daptomycin and vancomycin in an in vitro dynamic model
    Alexander A Firsov
    Department of Pharmacokinetics and Pharmacodynamics, Gause Institute of New Antibiotics, Russian Academy of Medical Sciences, 11 Bolshaya Pirogovskaya Street, Moscow, 119021 Russia
    J Antimicrob Chemother 58:1185-92. 2006

Collaborators

  • Stephen H Zinner
  • G Cornaglia
  • KARL A DRLICA
  • Yury A Portnoy
  • Irene Yu Lubenko
  • Sergey N Vostrov
  • Maria V Smirnova
  • M V Smirnova
  • Elena N Strukova
  • Irene Y Lubenko
  • Irene V Alferova
  • E N Strukova
  • M B Kobrin
  • Y A Portnoy
  • S A Dovzhenko
  • Elena V Strukova

Detail Information

Publications35

  1. pmc Bacterial resistance studies using in vitro dynamic models: the predictive power of the mutant prevention and minimum inhibitory antibiotic concentrations
    Alexander A Firsov
    Department of Pharmacokinetics and Pharmacodynamics, Gause Institute of New Antibiotics, Russian Academy of Medical Sciences, Moscow, Russia
    Antimicrob Agents Chemother 57:4956-62. 2013
    ..This implies that AUC24/MPC might be a better interspecies predictor of bacterial resistance than AUC24/MIC. ..
  2. doi request reprint Telavancin and vancomycin pharmacodynamics with Staphylococcus aureus in an in vitro dynamic model
    Irene Yu Lubenko
    Department of Pharmacokinetics and Pharmacodynamics, Gause Institute of New Antibiotics, Russian Academy of Medical Sciences, 11 Bolshaya Pirogovskaya Street, Moscow 119021, Russia
    J Antimicrob Chemother 62:1065-9. 2008
    ..Their concentrations were simulated between the MIC and the mutant prevention concentration (MPC), and above the MPC...
  3. doi request reprint Linezolid pharmacodynamics with Staphylococcus aureus in an in vitro dynamic model
    Elena N Strukova
    Department of Pharmacokinetics and Pharmacodynamics, Gause Institute of New Antibiotics, Russian Academy of Medical Sciences, Moscow, Russia
    Int J Antimicrob Agents 33:251-4. 2009
    ..95. The established AUC(24)/MIC-I(E) relationship is useful to predict the antistaphylococcal effects of linezolid at clinically attainable AUC(24)/MIC values...
  4. pmc Comparative pharmacodynamics and antimutant potentials of doripenem and imipenem with ciprofloxacin-resistant Pseudomonas aeruginosa in an in vitro model
    Alexander A Firsov
    Department of Pharmacokinetics and Pharmacodynamics, Gause Institute of New Antibiotics, Russian Academy of Medical Sciences, Moscow, Russia
    Antimicrob Agents Chemother 56:1223-8. 2012
    ..However, doripenem appeared to be somewhat more efficient than imipenem at clinically achievable AUC(24)s related to the means of the MICs for the three studied strains and had higher antimutant potentials for two of the three strains...
  5. ncbi request reprint ABT492 and levofloxacin: comparison of their pharmacodynamics and their abilities to prevent the selection of resistant Staphylococcus aureus in an in vitro dynamic model
    Alexander A Firsov
    Department of Pharmacokinetics and Pharmacodynamics, Gause Institute of New Antibiotics, Russian Academy of Medical Sciences, 11 Bolshaya Pirogovskaya Street, Moscow, 119021
    J Antimicrob Chemother 54:178-86. 2004
    ..To compare the kinetics of killing/regrowth of differentially susceptible clinical isolates of Staphylococcus aureus exposed to ABT492 and levofloxacin and to explore their relative abilities to prevent the selection of resistant mutants...
  6. ncbi request reprint AUC/MIC relationships to different endpoints of the antimicrobial effect: multiple-dose in vitro simulations with moxifloxacin and levofloxacin
    Alexander A Firsov
    Department of Pharmacokinetics and Pharmacodynamics, Gause Institute of New Antibiotics, Russian Academy of Medical Sciences, 11 Bolshaya Pirogovskaya Street, Moscow, 119992 Russia
    J Antimicrob Chemother 50:533-9. 2002
    ..Similar limitations of the tau-related endpoints might be critical in comparative studies with other new fluoroquinolones where therapeutic AUCtau/MIC ratios are >100 h...
  7. pmc Enrichment of fluoroquinolone-resistant Staphylococcus aureus: oscillating ciprofloxacin concentrations simulated at the upper and lower portions of the mutant selection window
    Alexander A Firsov
    Department of Pharmacokinetics and Pharmacodynamics, Gause Institute of New Antibiotics, Russian Academy of Medical Sciences, 11 Bolshaya Pirogovskaya St, Moscow 119021, Russia
    Antimicrob Agents Chemother 52:1924-8. 2008
    ..aureus, depending on the position of simulated concentrations inside the MSW at a given T(MSW). This explains why T(MSW)-based predictions of resistance are less accurate than those based on AUC/MIC and AUC/MPC...
  8. ncbi request reprint Simulated in vitro quinolone pharmacodynamics at clinically achievable AUC/MIC ratios: advantage of I E over other integral parameters
    A A Firsov
    Department of Pharmacokinetics and Pharmacodynamics, Gause Institute of New Antibiotics, Russian Academy of Medical Sciences, Moscow, Russia
    Chemotherapy 48:275-9. 2002
    ....
  9. pmc In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus
    Alexander A Firsov
    Department of Pharmacokinetics, Gause Institute of New Antibiotics, Russian Academy of Medical Sciences, Moscow, Russia
    Antimicrob Agents Chemother 47:1604-13. 2003
    ....
  10. ncbi request reprint Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to daptomycin and vancomycin in an in vitro dynamic model
    Alexander A Firsov
    Department of Pharmacokinetics and Pharmacodynamics, Gause Institute of New Antibiotics, Russian Academy of Medical Sciences, 11 Bolshaya Pirogovskaya Street, Moscow, 119021 Russia
    J Antimicrob Chemother 58:1185-92. 2006
    ....
  11. ncbi request reprint Prevention of the selection of resistant Staphylococcus aureus by moxifloxacin plus doxycycline in an in vitro dynamic model: an additive effect of the combination
    Alexander A Firsov
    Department of Pharmacokinetics and Pharmacodynamics, Gause Institute of New Antibiotics, Russian Academy of Medical Sciences, 11 Bolshaya Pirogovskaya Street, Moscow 119021, Russia
    Int J Antimicrob Agents 23:451-6. 2004
    ..aureus is proposed. The use of drug combinations may be useful for restricting the enrichment of resistant mutants with agents whose clinically achievable AUC(24)/MICs do not provide concentrations above the MPC...
  12. pmc Antistaphylococcal effect related to the area under the curve/MIC ratio in an in vitro dynamic model: predicted breakpoints versus clinically achievable values for seven fluoroquinolones
    Alexander A Firsov
    Department of Pharmacokinetics and Pharmacodynamics, Gause Institute of New Antibiotics, Russian Academy of Medical Sciences, 11 Bolshaya Pirogovskaya St, Moscow 119021, Russia
    Antimicrob Agents Chemother 49:2642-7. 2005
    ..The highest ratios of AUC(ther)/MIC50 to BP were achieved with TVA, MXF, and GEM (2.5 to 3.0); intermediate ratios (1.5 to 1.6) were achieved with GAT and GRX; and minimal ratios (0.3 to 1.2) were achieved with CIP and LVX...
  13. ncbi request reprint Concentration-dependent changes in the susceptibility and killing of Staphylococcus aureus in an in vitro dynamic model that simulates normal and impaired gatifloxacin elimination
    Alexander A Firsov
    Department of Pharmacokinetics and Pharmacodynamics, Gause Institute of New Antibiotics, Russian Academy of Medical Sciences, 11 Bolshaya Pirogovskaya Street, Moscow 119021, Russia
    Int J Antimicrob Agents 23:60-6. 2004
    ..This study predicts different protective potentials of gatifloxacin in IEK and NEK against staphylococcal resistance and supports the MSW concept...
  14. ncbi request reprint Comparative pharmacodynamics of azithromycin and roxithromycin with S. pyogenes and S. pneumoniae in a model that simulates in vitro pharmacokinetics in human tonsils
    Alexander A Firsov
    Department of Pharmacokinetics, Centre for Science and Technology LekBioTech, Russian Academy of Medical Sciences, Moscow, Russia
    J Antimicrob Chemother 49:113-9. 2002
    ..Further in vitro simulations of tissue pharmacokinetics might be useful for pharmacodynamic comparisons among other macrolides...
  15. doi request reprint Enrichment of resistant Staphylococcus aureus at ciprofloxacin concentrations simulated within the mutant selection window: bolus versus continuous infusion
    Alexander A Firsov
    Department of Pharmacokinetics and Pharmacodynamics, Gause Institute of New Antibiotics, Russian Academy of Medical Sciences, 11 Bolshaya Pirogovskaya Street, Moscow 119021, Russia
    Int J Antimicrob Agents 32:488-93. 2008
    ..This study indicates the mode of ciprofloxacin administration does not influence selection of resistant staphylococci, which is better predicted by AUC24/MPC than by AUC24/MIC...
  16. pmc Prediction of the effects of inoculum size on the antimicrobial action of trovafloxacin and ciprofloxacin against Staphylococcus aureus and Escherichia coli in an in vitro dynamic model
    A A Firsov
    Department of Pharmacokinetics, Center for Science and Technology LekBioTech, Moscow, Russia
    Antimicrob Agents Chemother 43:498-502. 1999
    ..The described approach to the analysis of the inoculum effect in in vitro dynamic models might be useful in studies with other antibiotic classes...
  17. ncbi request reprint Prediction of the antimicrobial effects of trovafloxacin and ciprofloxacin on staphylococci using an in-vitro dynamic model
    A A Firsov
    Department of Pharmacokinetics, Centre of Science and Technology LekBioTech, Moscow, Russia
    J Antimicrob Chemother 43:483-90. 1999
    ..These I(E)-log D relationships allow prediction of the effect of a given quinolone on a representative strain of the bacterial species...
  18. ncbi request reprint Comparative pharmacodynamics of moxifloxacin and levofloxacin in an in vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and equiefficient doses
    A A Firsov
    Department of Pharmacokinetics, Centre for Science and Technology LekBioTech, 8 Nauchny Proezd, Moscow 117246, Russia
    J Antimicrob Chemother 46:725-32. 2000
    ..The described method of generalization of data obtained with specific organisms to other representatives of the same species might be useful to predict the AMEs of new quinolones...
  19. ncbi request reprint Gemifloxacin and ciprofloxacin pharmacodynamics in an in-vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and doses
    A A Firsov
    Department of Pharmacokinetics, Centre for Science and Technology LekBioTech, 8 Nauchny Proezd, Moscow 117246, Russia
    Int J Antimicrob Agents 16:407-14. 2000
    ..It was calculated, that a daily dose of CIP that might provide the same AME as a clinical dose of GEM (320 mg) on a hypothetical strain of S. aureus with MICs=MIC(50)s would be as high as 2 x 3200 mg...
  20. pmc Relationships of the area under the curve/MIC ratio to different integral endpoints of the antimicrobial effect: gemifloxacin pharmacodynamics in an in vitro dynamic model
    A A Firsov
    Department of Pharmacokinetics, Centre of Science and Technology LekBioTech, Moscow, Russia
    Antimicrob Agents Chemother 45:927-31. 2001
    ..Since all of them respond to AUC/MIC ratio changes less than the I(E), the latter is preferable in comparative pharmacodynamic studies...
  21. ncbi request reprint Comparative pharmacodynamics of the new fluoroquinolone ABT492 and levofloxacin with Streptococcus pneumoniae in an in vitro dynamic model
    Alexander A Firsov
    Department of Pharmacokinetics and Pharmacodynamics, Gause Institute of New Antibiotics, Russian Academy of Medical Sciences, 11 Bolshaya Pirogovskaya Street, Moscow 119021, Russia
    Int J Antimicrob Agents 25:409-13. 2005
    ..pneumoniae and similar efficacies of the two quinolones against susceptible organisms...
  22. pmc Inter- and intraquinolone predictors of antimicrobial effect in an in vitro dynamic model: new insight into a widely used concept
    A A Firsov
    Department of Pharmacokinetics, Centre of Science and Technology LekBioTech, Moscow, Russia
    Antimicrob Agents Chemother 42:659-65. 1998
    ..Teff may be able to accurately predict the AME of one quinolone on the basis of the data obtained for another quinolone...
  23. pmc Parameters of bacterial killing and regrowth kinetics and antimicrobial effect examined in terms of area under the concentration-time curve relationships: action of ciprofloxacin against Escherichia coli in an in vitro dynamic model
    A A Firsov
    Department of Pharmacokinetics, Centre of Science and Technology, LekBioTech, Moscow, Russia
    Antimicrob Agents Chemother 41:1281-7. 1997
    ..Thus, use of I(E) and T(E) provides the most unbiased, robust, and comprehensive means of determining the antimicrobial effect...
  24. pmc Quantitative analysis of antimicrobial effect kinetics in an in vitro dynamic model
    A A Firsov
    Department of Pharmacokinetics, National Research Institute of Antibiotics, Moscow, USSR
    Antimicrob Agents Chemother 34:1312-7. 1990
    ....
  25. pmc MIC-based interspecies prediction of the antimicrobial effects of ciprofloxacin on bacteria of different susceptibilities in an in vitro dynamic model
    A A Firsov
    Department of Pharmacokinetics, Centre of Science and Technology LekBioTech, Moscow, Russia
    Antimicrob Agents Chemother 42:2848-52. 1998
    ..Teff was shown previously also to be the best interquinolone predictor, but unlike AUC/MIC, it cannot be used to compare different quinolones. AUC/MIC might be the best predictor of the AME in comparisons of different quinolones...
  26. ncbi request reprint The antistaphylococcal pharmacodynamics of linezolid alone and in combination with doxycycline in an in vitro dynamic model
    M V Smirnova
    Department of Pharmacokinetics and Pharmacodynamics, Gause Institute of New Antibiotics, Russian Academy of Medical Sciences, Moscow, Russia
    J Chemother 23:140-4. 2011
    ..This study suggests that linezolid combinations with doxycycline may be synergistic in treating staphylococcal infections...
  27. pmc A new approach to in vitro comparisons of antibiotics in dynamic models: equivalent area under the curve/MIC breakpoints and equiefficient doses of trovafloxacin and ciprofloxacin against bacteria of similar susceptibilities
    A A Firsov
    Department of Pharmacokinetics, Centre of Science and Technology LekBioTech, Moscow 117246, Russia
    Antimicrob Agents Chemother 42:2841-7. 1998
    ....
  28. pmc Relationships between antimicrobial effect and area under the concentration-time curve as a basis for comparison of modes of antibiotic administration: meropenem bolus injections versus continuous infusions
    A A Firsov
    Department of Pharmacokinetics, Centre of Science and Technology LekBioTech, Moscow, Russia
    Antimicrob Agents Chemother 41:352-6. 1997
    ..Such comparative studies should be designed in a manner that provides the use of similar AUC ranges, since the AUC may be considered as a common pharmacokinetic denominator in comparing one MA or dosing regimen to another...
  29. ncbi request reprint Comparative pharmacodynamics of the new fluoroquinolone ABT492 and ciprofloxacin with Escherichia coli and Pseudomonas aeruginosa in an in vitro dynamic model
    Stephen H Zinner
    Department of Medicine, Mount Auburn Hospital, Harvard Medical School, Cambridge, MA, USA
    Int J Antimicrob Agents 24:173-7. 2004
    ..These findings predict comparable efficacies of clinically achievable AUC/MICs of ABT492 and ciprofloxacin against E. coli (q.d. versus b.i.d. quinolone dosing) and P. aeruginosa at b.i.d. but not at q.d. ABT492...
  30. ncbi request reprint Bacterial strain-independent AUC/MIC and strain-specific dose-response relationships reflecting comparative fluoroquinolone anti-pseudomonal pharmacodynamics in an in vitro dynamic model
    Irene Yu Lubenko
    Department of Pharmacokinetics and Pharmacodynamics, Gause Institute of New Antibiotics, 11 Bolshaya Pirogovskaya Street, Moscow 119992, Russia
    Int J Antimicrob Agents 20:44-9. 2002
    ..This study suggests that both bacterial strain-independent AUC/MIC- and the respective strain-specific dose-response relationships of the AME are important for comprehensive pharmacodynamic evaluation of antimicrobial agents...
  31. ncbi request reprint Species-independent pharmacodynamics of gemifloxacin and ciprofloxacin with Haemophilus influenzae and Moraxella catarrhalis in an in vitro dynamic model
    Yury A Portnoy
    Department of Pharmacokinetics and Pharmacodynamics, Gause Institute of New Antibiotics, Russian Academy of Medical Sciences, 11 Bolshaya Pirogovskaya Street, Moscow 119992, Russia
    Int J Antimicrob Agents 20:201-5. 2002
    ..These data suggest greater efficacy of gemifloxacin against H. influenzae and M. catarrhalis relative to ciprofloxacin at clinically achievable AUC/MIC ratios...
  32. doi request reprint Selection of linezolid-resistant Enterococcus faecium in an in vitro dynamic model: protective effect of doxycycline
    Stephen H Zinner
    Mount Auburn Hospital, Harvard Medical School, Cambridge, MA, USA
    J Antimicrob Chemother 61:629-35. 2008
    ..e. the concentration range from the MIC to the mutant prevention concentration (MPC)...
  33. ncbi request reprint Concentration-response relationships as a basis for choice of the optimal endpoints of the antimicrobial effect: daptomycin and vancomycin pharmacodynamics with staphylococci in an in vitro dynamic model
    Maria V Smirnova
    Department of Pharmacokinetics and Pharmacodynamics, Gause Institute of New Antibiotics, Russian Academy of Medical Sciences, 11 Bolshaya Pirogovskaya Street, Moscow 119021, Russia
    Int J Antimicrob Agents 29:165-9. 2007
    ..The better abilities of ABBC and N(min) and the inability of T(90%) and T(99%) to provide reasonable AUC/MIC relationships with DAP and VAN support earlier findings reported with fluoroquinolones...
  34. ncbi request reprint Comparative pharmacodynamics of telithromycin and clarithromycin with Streptococcus pneumoniae and Staphylococcus aureus in an in vitro dynamic model: focus on clinically achievable antibiotic concentrations
    Irene V Alferova
    Department of Pharmacokinetics and Pharmacodynamics, Gause Institute of New Antibiotics, Russian Academy of Medical Sciences, 11 Bolshaya Pirogovskaya Street, Moscow 119021, Russia
    Int J Antimicrob Agents 26:197-204. 2005
    ..aureus, treatment for 3 days with telithromycin was not accompanied by a loss in susceptibility, whereas the enrichment of resistant staphylococci occurred with one of the two clarithromycin-treated strains...
  35. ncbi request reprint Emergence of resistant Streptococcus pneumoniae in an in vitro dynamic model that simulates moxifloxacin concentrations inside and outside the mutant selection window: related changes in susceptibility, resistance frequency and bacterial killing
    Stephen H Zinner
    Department of Medicine, Mount Auburn Hospital, Harvard Medical School, Cambridge, MA, USA
    J Antimicrob Chemother 52:616-22. 2003
    ..To test this hypothesis, Streptococcus pneumoniae ATCC 49619 (MIC 0.1 mg/L; MPC 0.5 mg/L) was exposed to moxifloxacin concentrations below the MIC, above the MPC and between the MIC and MPC, i.e. within the MSW...